Clinical Trial

FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is an open-label, multicenter study designed to investigate the efficacy, safety and tolerability of FPI-2265 (225Ac-PSMA-I\&T) in combination with Olaparib in participants with mCRPC. The dose optimization Phase 2 part will be investigating the safety, tolerability, and anti-tumor activity of novel dosing regimens of FPI-2265 and Olaparib in participants with metastatic castration-resistant prostate cancer.
Protocol Amendment History 2 changes
notable Primary completion moved earlier: 2030-01-29 -> 2027-05 2026-05-07
minor Completion moved earlier: 2030-08-12 -> 2027-05 2026-05-07
Trial Details
NCT Number NCT06909825
Lead Sponsor Fusion Pharmaceuticals Inc.
Conditions Metastatic Castration-resistant Prostate Cancer
Enrollment 85 participants
Start Date 2025-02-26
Primary Completion 2027-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-04